Journal
JOURNAL OF INFLAMMATION RESEARCH
Volume 14, Issue -, Pages 5611-5618Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JIR.S329252
Keywords
biologics; COVID-19; psoriasis; therapy; IL-17
Categories
Ask authors/readers for more resources
Studies have shown that IL-17 inhibitors play a key role in alleviating or preventing cytokine storms in COVID-19 patients, while also helping to better understand the effects of drugs on the immune system.
The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available